Menu
View Cart  

Recommended Products

Visit Store
Eu-mdr-compliance-130x160

EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements

The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating-generic-drug-development-130x160

Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition

Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.

Events

View All
Sep 24

Drug Regulation in China: Updates, Key Issues and Common Challenges

Sep 25

The AI Revolution: What You Must Know About Medical Imaging Regulation

Sep 27

Using IT to Improve Data Integrity: Optimizing Your Compliance Joint IT/QA Programs

Sep 27

FDA and EU Inspections — The Mutual Recognition Agreement: What’s Next?

Oct 1

Advanced GMP Training: The Seven Essentials for Compliance

Oct 4

Transparency and the New Medical Device Reporting Rules: What to Do Now That ASR is Really Over

Editor's Picks

View all
Fda_logo_blue_2016

FDA Seeks Input on Risk-Benefit Reviews for Weight Loss Devices

The FDA said it “continues to receive a high volume of pre-submissions from industry requesting feedback about the necessary data to support pivotal clinical studies and marketing applications for a wide variety of device designs intended for weight loss.”
Redwarningstamp

Costa Rican OTC Drugmaker Hit for Testing, Stability Program

The company said it would employ a third-party testing laboratory, but it didn’t provide a description of the test it would conduct.

BIOMIRA REPORTS LUNG CANCER DRUG STUDY RESULTS

KEYWORDS Drug Pipeline Alert
A A

Biomira has reported results from a clinical trial of its non-small cell lung cancer drug, Stimuvax.

The final survival results from an analysis of the Phase IIb data confirmed a median survival in patients with Stage IIIB cancer of 30.6 months with Stimuvax, while patients in the same stage who were in a control test group had a median survival of 13.3 months.